Navigation Links
Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy

Larynx cancer patients treated with alternating cycles of chemotherapy and radiation have similar outcomes to patients treated with chemotherapy followed by radiation, according to data from a randomized controlled trial in the January 27 online issue of the Journal of the National Cancer Institute.

Previous trials in patients with locally advanced larynx cancer showed that chemotherapy followed by radiation was as effective as total removal of the larynx, known as laryngectomy, in terms of overall and disease-free survival and that this sequential therapy provided better quality of life. Subsequent trials indicated that concurrent administration of chemotherapy and radiation resulted in a statistically significant improvement in larynx preservation but was associated with more serious acute toxicity and possibly long term side effects.

To try to improve patient survival without increasing side effects, Jean Lefebvre, M.D., of the Centre Oscar Lambret in Lille, France, and colleagues in the European Organization for Research and Treatment of Cancer enrolled 450 patients with larynx or hypopharynx cancer in a randomized controlled trial. Patients received either chemotherapy followed by radiation or alternating cycles of radiation and chemotherapy.

With a median follow-up of 6.5 years, there was no significant difference in clinical outcomes between the two treatment groups. Larynx preservation, overall survival, and progression-free survival were similar for patients treated with sequential and alternating chemotherapy and radiation.

"The aim of our trial was to identify a regimen that would mimic concomitant chemotherapy and radiotherapy without its increased toxic effects," the authors write. "Although we achieved the latter goalefficacy was not improved." Given the results of this and several other recently-completed trials, the authors conclude that an optimal approach for larynx-preserving therapy has not been identified.

In an accompanying editorial, Arlene Forastiere, M.D., and Andy Trotti, M.D., of the Sidney Kimmel Cancer Center at Johns Hopkins University in Baltimore and the H. Lee Moffitt Cancer Center at the University of South Florida in Tampa, respectively, concur with that conclusion. The editorialists put the newly-reported data into context, reviewing other trials in the field. They note, however, that because the field currently lacks shared definitions and endpoints, synthesis of data from all the trials is difficult.

"In summary, the [current] trial showed no advantage for alternating chemotherapy and radiotherapy over traditional cisplatin plus 5-fluorouracil induction chemotherapy in hypopharynx cancer," the editorialists write. "More effective and less toxic approaches are needed. This trial also illustrates the need for common definitions and metrics to facilitate interpretation and to compare results across trials."


Contact: Caroline McNeil
Journal of the National Cancer Institute

Related medicine news :

1. Alternating mammography and MRI may be best for high-risk women
2. How chemotherapy drugs block blood vessel growth, slow cancer spread
3. UNC study supports role of circadian clock in response to chemotherapy
4. Gene Governs Response to Leukemia Chemotherapy
5. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
6. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
7. Studies show novel device may enhance chemotherapy treatment in brain tumors
8. Iressa as Good as Chemotherapy for Lung Cancer
9. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
10. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
11. SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... , ... November 26, 2015 , ... ... Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public ... in Nairobi (UNON) for the opening of the 5th African Network for Drugs ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to become more ... to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be ... As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... “While riding ... an inventor, from Bronx, N.Y. “I thought there had to be a convenient and ... the PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... by Type (Dressings, Therapy Devices, Active Wound Care), Application ... and Geography - Global Forecast to 2020" report ... --> The purpose of this report is ... global advanced wound care market. It involves deep dive ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
Breaking Medicine Technology: